YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

[Rationale]: The characterization of new genetic alterations is essential to assign effective personalized therapies in non–small cell lung cancer (NSCLC). Furthermore, finding stratification biomarkers is essential for successful personalized therapies. Molecular alterations of YES1, a member of th...

Descripción completa

Detalles Bibliográficos
Autores: Garmendia, Irati, Pajares, María J., Hermida-Prado, Francisco, Ajona, Daniel, Bértolo, Cristina, Sainz, Cristina, Lavín, Amaya, Remírez, Ana B., Valencia, Karmele, Moreno, Haritz, Ferrer, Irene, Behrens, Carmen, Cuadrado, Myriam, Paz-Ares, Luis, Bustelo, Xosé R., Gil-Bazo, Ignacio, Alameda, Daniel, Lecanda, Fernando, Calvo, Alfonso, Felip, Enriqueta, Sánchez-Céspedes, M., Wistuba, Ignacio I., Granda-Díaz, Rocío, Rodrigo, Juan Pablo, García-Pedrero, Juana María, Pio, Rubén, Montuenga, Luis M., Agorreta, Jackeline
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/219735
Acceso en línea:http://hdl.handle.net/10261/219735
Access Level:acceso abierto
Palabra clave:Dasatinib
Lung cancer
YES1
Src family kinases
Predictive biomarker
Descripción
Sumario:[Rationale]: The characterization of new genetic alterations is essential to assign effective personalized therapies in non–small cell lung cancer (NSCLC). Furthermore, finding stratification biomarkers is essential for successful personalized therapies. Molecular alterations of YES1, a member of the SRC (proto-oncogene tyrosine-protein kinase Src) family kinases (SFKs), can be found in a significant subset of patients with lung cancer.

Similares en LA Referencia